SBIR/STTR Research Award

Artiodactyl Gene Modification with Tal Effector Nucleases

Award identifier 9f28c9fa88080a9df805b587f60f2b80df97b9cf98bdaa1fc215dc89fd5b544bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$232,864

Program and phase

SBIR · Phase I

Award year

2012

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Recombinetics, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
L99NWZNZ7K57
Solicitation number
PA11-096
Topic code
OD

Research abstract

DESCRIPTION (provided by applicant): Large animal models of human disease are indispensible for the development of relevant preclinical therapeutic protocols. Gene inactivation and gene conversion are powerful approaches for creating genocopies of allelesthat cause disease in patients and for the modification of genes for biomedical materials development. A DNA double strand break (DSB) at a desired genome location is a flexible substrate for genome engineering, enabling; mutation of a target sequence, targeted integration of transgenes, or the stimulation of gene conversion by homologous recombination (HR) with a repair template. Consequently, the tools for genome engineering are rapidly converging on the concept of DSB induction using a variety of technologies, including the widely publicized Zinc-Finger Nucleases (ZFN) and Meganuclease (MGN) platforms. While both MGN and ZFN are efficient and reasonably precise, significant limitations in targetable sites, difficulty in developing new enzymes, and a constrained IP landscape limit their widespread commercial application. The recently described TAL effector nucleases (TALENs) are a novel DSB-inducing platform that appears to be easier to deploy and with a greater flexibility in target site selection, since their modular DNA binding motifs enable localization of nuclease activity to a broad range of targets. Recombinetics proposes to investigate enablement of TALENs for gene inactivation and, in combination with RCI technologies to stimulate gene conversion in livestock cells and embryos. The studies proposed here will establish a new paradigm for the genetic modification of artiodactyls (pigs, sheep, and cattle) for use as large animal models of human disease and the production of biomedical materials.PUBLIC HEALTH RELEVANCE: Large animal models of human disease are indispensible for the development of relevant preclinical therapeutic protocols. We propose to investigate enablement of TALENs for gene inactivation in livestock cells and, in combination with RCI technologies to stimulate gene conversion in livestock cells and embryos. The studies proposed here will establish a new paradigm for the genetic modification of artiodactyls (pigs, sheep, and cattle) for use as large animal models of human disease.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

20 SBIR/STTR records share this UEI (2011–2024). Reported award amounts total $9,634,813. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.